Obesity Biomarker Screening Array Service
InquiryDeciphering the intricate cross-talk between adipose tissue and systemic metabolic regulators is essential for modern drug development. Protheragen offers a specialized multiplex adipokine & metabolic signaling array service, providing preclinical researchers with a high-throughput solution to map the secretory profile of metabolic disorders.
Multiplex Adipokine & Metabolic Signaling Array Service
Our platform enables the simultaneous quantification of dozens of essential biomarkers—ranging from appetite-regulating peptides to pro-inflammatory cytokines—from a single, micro-volume specimen. By utilizing high-density antibody arrays, we provide a holistic view of the metabolic state, allowing for the rapid identification of therapeutic efficacy and mechanism-of-action insights in animal models.
Core Technologies
Protheragen utilizes advanced antibody-based microarray platforms and ultra-sensitive detection systems to deliver high-quality data. Our core technology leverages sandwich-based chemiluminescence and fluorescence-linked immunosorbent assays integrated into a high-throughput glass slide or membrane format.
- Multiplex Protein Microarrays
These arrays utilize high-affinity capture antibodies spotted in duplicate, allowing for the simultaneous quantification of adipokines, inflammatory markers, and appetite-regulating hormones.
- Digital Immunoassay Integration
For low-abundance biomarkers that often escape detection in standard ELISA, we employ digital-level sensitivity platforms that offer a dynamic range up to 1000-fold greater than conventional methods.
- High-Specificity Validation
Every antibody pair used in our obesity screening array is rigorously cross-validated to eliminate non-specific binding and interference, ensuring that the results from complex preclinical matrices (such as serum or tissue lysates) are both accurate and reproducible.
Service Scope
The Protheragen obesity biomarker screening array service covers an extensive range of metabolic and inflammatory markers, categorized into functional groups:
- Adipokines
Leptin, adiponectin, resistin, chemerin, and visfatin.
- Appetite and Glucose Regulators
Insulin, glucagon, GLP-1, ghrelin, and PYY.
- Inflammatory Cytokines
TNF-ɑ, IL-6, MCP-1, and CRP.
- Growth and Angiogenesis Factors
IGF-1, VEGF, and angiopoietin-like proteins.
- Lipid Metabolism Markers
FABP4, ApoE, and LPL.
Workflow
Our streamlined service process is designed to integrate seamlessly into your preclinical study timeline, ensuring data integrity from sample receipt to final reporting.
Contact Us to Streamline Your Preclinical Data Collection
Fields of Application
Our obesity biomarker screening array service provides critical insights across various research domains, from early-stage target identification to the evaluation of metabolic drug efficacy in specialized animal models
- Drug Discovery: Screening lead compounds for their ability to modulate adipokine secretion or suppress chronic inflammation.
- Mechanism of Action (MoA) Studies: Identifying which specific signaling pathways (e.g., JAK/STAT or NF-κB) are influenced by a therapeutic intervention.
- Toxicological Assessment: Monitoring for off-target metabolic effects during safety profiling in Preclinical Models.
- Nutraceutical Research: Evaluating the impact of dietary interventions on systemic metabolic health.
- Biomarker Discovery: Identifying early-stage indicators of insulin resistance or metabolic syndrome in high-fat diet models.
Advantages
Protheragen provides a distinct edge in preclinical obesity research through our commitment to sensitivity and breadth of analysis. Our platforms require minimal sample volume (as low as 20–50 µL), which is vital for longitudinal studies involving small animal models where sample availability is limited.
Comprehensive Profiling
Rather than viewing endocrine markers in isolation, Protheragen utilizes advanced multiplexing to capture a holistic systems-biology view. By measuring appetite regulators (e.g., ghrelin, PYY), adipokines (e.g., leptin, adiponectin), and glycemic markers simultaneously, we provide a high-resolution map of the "metabolic crosstalk" between the gut, adipose tissue, and brain. This allows researchers to identify compensatory mechanisms and secondary effects that single-plex assays often miss.
Exceptional Sensitivity
Our platform achieves detection limits at the sub-picogram per milliliter level. This ultra-sensitivity is critical for identifying subtle physiological fluctuations and early-stage biomarker shifts before they manifest as gross phenotypic changes, such as weight gain or glucose intolerance. This capability provides a wider therapeutic window for evaluating drug efficacy in the earliest stages of obesity progression.
Reliability
Protheragen’s multiplex approach is engineered for maximum reproducibility without compromising accuracy. By utilizing a single-well environment for dozens of analytes, we drastically reduce inter-assay variability and eliminate the technical noise inherent in running multiple independent experiments.
Accelerated Timelines
Time is a critical resource in preclinical development. By processing dozens of analytes in a single automated run, we reduce the experimental footprint and data turnaround time by up to 70%. This acceleration enables rapid iteration during lead optimization and ensures that critical "go/no-go" decisions are backed by comprehensive data weeks earlier than traditional methods allow.
Contact Protheragen Today to Receive a Customized Quote for Your Obesity Research Project.
Customer Review
Enhancing Lead Optimization with Multiplex Insights
"Working with Protheragen has transformed our approach to screening GLP-1 analogues. Previously, we were limited by the volume of serum we could collect from our mouse models, forcing us to choose only two or three markers to track. The obesity biomarker screening array allowed us to monitor 30 different adipokines and inflammatory markers from the same sample."
Dr. S. P., Biopharmaceutical Lead Discovery
Uncovering Subtle Metabolic Signaling
"Working with Protheragen was a seamless experience. Their technical support helped us optimize our tissue lysis protocol, which was crucial for getting clean signals from our fibrotic liver samples. The comprehensive report they provided saved our team weeks of data processing. They are our go-to partner for high-throughput protein profiling in preclinical discovery."
Dr. D. H. M., Global Institute of Health
Frequently Asked Questions
-
What sample types are compatible with the obesity array?
We primarily work with preclinical serum, plasma, cell culture supernatants, and various tissue homogenates, specifically white and brown adipose tissue.
-
How much sample volume do I need to provide?
Our multiplex technology is highly efficient; usually, 50 µL of serum is sufficient for a full profile in duplicate.
-
Can I customize the array to include specific markers of interest?
Yes, Protheragen offers flexible panel configurations where you can add or swap specific biomarkers relevant to your unique study.
-
What is the typical turnaround time for a screening project?
Most preclinical screening projects are completed, including data analysis, within 2 to 3 weeks of sample receipt.
-
Are the results quantitative or semi-quantitative?
We provide fully quantitative data with concentration values (e.g., pg/mL) based on calibrated standard curves for each analyte.
-
How do you handle high-lipid samples common in obesity research?
We utilize specialized pre-clearing protocols to ensure that high lipid content does not interfere with antibody binding or signal detection.
-
Do you provide bioinformatic support?
Absolutely. Our reports include statistical analysis, such as T-tests or ANOVA, and visual tools like heat maps and PCA plots.
-
Is this service available for human clinical samples?
No, our current facilities and workflows are strictly dedicated to supporting preclinical research and animal model studies.
-
How does your array compare to a standard ELISA?
Our array provides the same level of specificity as an ELISA but allows for the detection of up to 40+ markers simultaneously, saving time, cost, and sample volume.
Contact Us
Protheragen is dedicated to providing the high-resolution molecular data necessary to advance the field of obesity research. Our specialized arrays and expert bioinformatics team ensure that your preclinical studies are supported by robust, reproducible, and actionable evidence.
Contact Protheragen for More Information and to Discuss Your Project
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.